drugset / Trial / NCT07614646
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients
NaSequentialOpen-labelTreatment
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) combination with Ivonescimab in patients with sq-NSCLC.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-07
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EVM14 | Vaccine | — | Intramuscular |
| Background | Ivonescimab | Monoclonal antibody | 200 mg | Intravenous |